Hartford Investment Management Co. acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,417 shares of the specialty pharmaceutical company’s stock, valued at approximately $200,000.

A number of other hedge funds also recently bought and sold shares of JAZZ. Renaissance Technologies LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 1,044.1% in the first quarter. Renaissance Technologies LLC now owns 215,100 shares of the specialty pharmaceutical company’s stock worth $28,081,000 after buying an additional 196,300 shares during the last quarter. State Street Corp increased its stake in shares of Jazz Pharmaceuticals PLC by 7.7% in the first quarter. State Street Corp now owns 1,333,938 shares of the specialty pharmaceutical company’s stock worth $174,128,000 after buying an additional 95,849 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 7.9% in the first quarter. Geode Capital Management LLC now owns 397,625 shares of the specialty pharmaceutical company’s stock worth $51,880,000 after buying an additional 29,119 shares during the last quarter. Springbok Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals PLC by 21.8% in the first quarter. Springbok Capital Management LLC now owns 2,120 shares of the specialty pharmaceutical company’s stock worth $277,000 after buying an additional 380 shares during the last quarter. Finally, HBK Investments L P acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth $980,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.38% during midday trading on Friday, reaching $126.04. 1,072,367 shares of the company’s stock traded hands. The firm has a market cap of $7.63 billion, a PE ratio of 22.16 and a beta of 0.93. The firm’s 50-day moving average is $135.28 and its 200 day moving average is $139.68. Jazz Pharmaceuticals PLC has a 52-week low of $108.50 and a 52-week high of $165.15.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.80 by $0.17. The company had revenue of $381 million for the quarter, compared to the consensus estimate of $376.40 million. Jazz Pharmaceuticals PLC had a net margin of 25.46% and a return on equity of 28.39%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the company earned $2.41 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current fiscal year.

A number of brokerages have weighed in on JAZZ. Mizuho reiterated a “buy” rating and set a $185.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Thursday. BMO Capital Markets reissued an “outperform” rating and set a $195.00 price objective (up previously from $193.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, September 8th. Leerink Swann reissued an “outperform” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 7th. Janney Montgomery Scott started coverage on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 25th. They set a “neutral” rating on the stock. Finally, Deutsche Bank AG reissued a “buy” rating and set a $158.00 price objective (up previously from $155.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $185.67.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul Treacy sold 1,292 shares of the stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $137.47, for a total transaction of $177,611.24. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.